TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on June 18, 2024, TransMedics granted non-qualified stock options to purchase an aggregate of 1,002 shares of its common stock and an aggregate of 657 restricted stock units to 1 employee, each as a material inducement for the employee's entry into employment with TransMedics. The grants
When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?
Director Edward Basile of TransMedics Group Inc (NASDAQ:TMDX) sold 1,193 shares of the company on June 5, 2024, according to a recent SEC Filing.